Ramzan Zakir, MD
Cardiovascular Disease · New Brunswick, NJNPI 1659579274
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 23.2%. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,256 payments — averaging $272.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$80K
- Boston Scientific$64K
- Angiodynamics, Inc.$55K
- Abbott$38K
- Cardiovascular Systems Inc.$31K
- Philips North America LLC$15K
- plus $60K from 54 others
Across 12 payments — averaging $3406.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Philips North America LLC$31K
- Veryan Medical Incorporated$8K
- Medalliance LLC$2K
- Abiomed$348
What the payments were for
- Consulting fees$80,80024%
- Speaking & faculty fees$132,71539%
- Travel & lodging$29,1169%
- Food & beverage$53,76816%
- Education$250%
- Other$45,58313%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$67,933
- Auryon Laser System 100-120 Vac$49,507
- Diamondback Peripheral$19,763
- GENERAL - THERAPIES$11,597
- GENERAL VASCULAR ACCESS$11,498
- ELUVIA$10,365
- ENDOCROSS Device$10,288
- Torus Stent Graft System$10,288
- Vascular Lithotripsy$10,266
- Omnilink Elite vascular stent system$9,000
- Peripheral Orbital Atherectomy System$7,570
- (9520) IGT Devices Undivided$7,311
- Indigo System$6,775
- GENERAL VASCULAR INTERVENTION$5,742
- Indigo$5,661
- DRAGONFLY OPSTAR$5,154
- Coronary Orbital Atherectomy System$5,096
- Impella$4,639
- Xience V coronary stent system$4,500
- ABSOLUTE PRO$4,500
How this compares
$342,008 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 218 | $254,438 |
| EntrestoSacubitril/Valsartan | 103 | $117,867 |
| Repatha SureclickEvolocumab | 73 | $67,057 |
| FarxigaDapagliflozin Propanediol | 47 | $48,541 |
| XareltoRivaroxaban | 50 | $48,396 |
| JardianceEmpagliflozin | 43 | $36,271 |
| MultaqDronedarone Hcl | 15 | $26,881 |
| BrilintaTicagrelor | 13 | $9,503 |
| Pitavastatin Calcium | 17 | $5,255 |
| Ranolazine ErRanolazine | 47 | $4,469 |
| Atorvastatin Calcium | 393 | $3,870 |
| Metoprolol Succinate | 271 | $3,606 |
| Nebivolol Hcl | 66 | $3,466 |
| Propafenone Hcl ErPropafenone Hcl | 12 | $1,712 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 97 | $1,547 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $85 | $254,438218 claims |
| NovartisEntresto | $476 | $117,867103 claims |
| AstraZenecaFarxiga, Brilinta | $707 | $58,04460 claims |
| Johnson & JohnsonXarelto | $27 | $48,39650 claims |
| Boehringer IngelheimJardiance | $37 | $36,27143 claims |
| Sanofi-aventis U.S. LLCMultaq | $58 | $26,88115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in New Brunswick
- John KostisNew Brunswick$225K
- Ashok ChaudharyNew Brunswick$144K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
- Fadi ChaabanWest Orange$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.